Signalling pathways involved in the control of sperm cell volume.
The ability to maintain cellular volume is an important general physiological function, which is achieved by specific molecular mechanisms. Hypotonically induced swelling results in the opening of K+ and Cl- ion channels, through which these ions exit with accompanying water loss. This process is known as regulatory volume decrease (RVD). The molecular mechanisms that control the opening of the ion channels in spermatozoa are as yet poorly understood. The present study investigated pathways of osmo-signalling using boar spermatozoa as a model. Spermatozoa were diluted into isotonic and hypotonic Hepes-buffered saline in the presence or absence of effector drugs, and at predetermined intervals volume measurements were performed electronically. Treatment with protein kinase C (PKC) inhibitors staurosporine, bismaleimide I and bismaleimide X led to dose-dependent increases of both isotonic and hypotonic volumes (P<0.05). However, as the isotonic volume was affected more than the hypotonic volume, the kinase inhibitors appeared to improve RVD, whereas activation of PKC with phorbol dibutyrate blocked RVD. The increase in isotonic cell volume induced by bismaleimide X was observed in chloride-containing medium but not in the medium in which chloride was replaced by sulphate, implying that PKC was involved in the control of chloride channel activity, e.g. by closing the channel after volume adjustment. The protein phosphatase PP1/PP2 inhibitors calyculin and okadaic acid increased the isotonic volume only slightly but they greatly increased the relative cell volume and blocked RVD. The activation of RVD processes was found to be cAMP-dependent; incubation with forskolin and papaverine improved volume regulation. Moreover, papaverine was able to overcome the negative effect of protein phosphatase inhibitors. The mechanism of sperm RVD appears to involve (a) alterations in protein phosphorylation/dephosphorylation balance brought about by PKC and PP1 and (b) a cAMP-dependent activating pathway.
Petrunkina
A M
AM
Unit for Reproductive Medicine of Clinics, Clinic for Horses, University of Veterinary Medicine Hannover Foundation, Bünteweg 15, 30559 Hannover, Germany. anna.petrunkina@tiho-hannover.de
Harrison
R A P
RA
Tsolova
M
M
Jebe
E
E
Töpfer-Petersen
E
E
D000818:Animals; D048429:Cell Size / Q000187:drug effects; D002478:Cells, Cultured; D018118:Chloride Channels / Q000378:metabolism; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D007473:Ion Channels / Q000187:drug effects; D008297:Male; D008301:Maleimides / Q000494:pharmacology; D008387:Marine Toxins; D019319:Okadaic Acid / Q000494:pharmacology; D009995:Osmosis; D010080:Oxazoles / Q000494:pharmacology; D010208:Papaverine / Q000494:pharmacology; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction; D013094:Spermatozoa / Q000166:cytology* / Q000378:metabolism*; D019311:Staurosporine / Q000494:pharmacology; D013552:Swine
D018118:Chloride Channels; D004791:Enzyme Inhibitors; D007211:Indoles; D007473:Ion Channels; D008301:Maleimides; D008387:Marine Toxins; D010080:Oxazoles; C116174:bisindolylmaleimide II; D005576:Colforsin; D019319:Okadaic Acid; C059041:calyculin A; D010208:Papaverine; D000242:Cyclic AMP; D011493:Protein Kinase C; D010749:Phosphoprotein Phosphatases; D019311:Staurosporine; C070515:bisindolylmaleimide I